Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China · Delayed Price · Currency is CNY 40.55
-5.50 (-11.94%)
Sep 5, 2025, 3:04 PM CST
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 62.38M CNY in the quarter ending June 30, 2025, a decrease of -28.63%. This brings the company's revenue in the last twelve months to 268.02M, down -28.94% year-over-year. In the year 2024, Staidson (Beijing) BioPharmaceuticals had annual revenue of 324.82M, down -10.81%.
Revenue (ttm)
268.02M
Revenue Growth
-28.94%
P/S Ratio
72.28
Revenue / Employee
544.76K
Employees
492
Market Cap
19.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | 425.21M | -236.28M | -35.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| WuXi AppTec | 41.90B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.94B |
| Shanghai United Imaging Healthcare | 10.98B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |